Nomura Asset Management
PDLI

Nomura Asset Management’s PDL BioPharma, Inc. PDLI Stock Holding History

Nomura Asset Management’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,600
Closed -$12K – 1410
2016
Q4 		$12K Buy
+5,600
New +$15.6K ﹤0.01% 1422

Other funds holding PDLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Nomura Asset Management's PDLI Position: Q1 2017 in Review

Nomura Asset Management sold out of PDL BioPharma, Inc. (PDLI) in Q1 2017, closing a stake of 5,600 shares — an estimated $12K sold.

Nomura Asset Management first reported a position in PDLI in Q4 2016 and held it in 1 quarter. The position peaked at $12K in Q4 2016. 174 funds tracked by Wall St. Rank hold PDLI as of Q1 2017.

  • Nomura Asset Management reported no remaining PDL BioPharma, Inc. position as of Q1 2017 after selling out during the quarter.
  • Nomura Asset Management sold 5,600 PDL BioPharma, Inc. shares in Q1 2017, an estimated $12K.
  • Nomura Asset Management first reported a position in PDL BioPharma, Inc. in Q4 2016 and held it in 1 quarter.
  • Nomura Asset Management's PDL BioPharma, Inc. position peaked at $12K in Q4 2016.
  • 174 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q1 2017.

Based on Nomura Asset Management's 13F filing for Q1 2017, filed 12 May 2017.